The current therapies we have available for schizophrenia are very effective at reducing psychotic symptoms in most patients, but for about 30 percent of patients, adverse events and suboptimal treatment responses can take a heavy toll. Could emerging therapies help us address these unmet needs? Learn more about the efficacy and tolerability limitations of current treatment options and what’s on the horizon with Dr. Charles Turck and Dr. Philip Harvey from the University of Miami Miller School of Medicine.